TP53 and hepatocellular carcinoma: Compared to colchicine, TCD exhibited enhanced antitumor activity (IC50<50 nM) in different human HCC cell lines (Table 1), specifically the p53-null Hep-3B line, which is infected with the hepatitis B virus (HBV) [36], and the well-differentiated Huh7 cell line [37].